Literature DB >> 18058241

Molecular dynamics studies of alpha-helix stability in fibril-forming peptides.

Erik Nordling1, Yvonne Kallberg, Jan Johansson, Bengt Persson.   

Abstract

Diseases associated with protein fibril-formation, such as the prion diseases and Alzheimer's disease, are gaining increased attention due to their medical importance and complex origins. Using molecular dynamics (MD) simulations in an aqueous environment, we have studied the stability of the alpha-helix covering positions 15-25 of the amyloid beta-peptide (A beta) involved in Alzheimer's disease. The effects of residue replacements, including the effects of A beta disease related mutations, were also investigated. The MD simulations show a very early (2 ns) loss of alpha-helical structure for the Flemish (A beta(A21G)), Italian (A beta(E22K)), and Iowa (A beta(D23N)) forms associated with hereditary Alzheimer's disease. Similarly, an early (5 ns) loss of alpha-helical structure was observed for the Dutch (A beta(E22Q)) variant. MD here provides a possible explanation for the structural changes. Two variants of A beta, A beta(K16A,L17A,F20A) and A beta(V18A,F19A,F20A), that do not produce fibrils in vitro were also investigated. The A beta(V18A,F19A,F20A) initially loses its helical conformation but refolds into helix several times and spends most of the simulation time in helical conformation. However, the A beta(K16A,L17A,F20A) loses the alpha-helical structure after 5 ns and does not refold. For the wildtype A beta(1-40) and A beta(1-42), the helical conformation is lost after 5 ns or after 40 ns, respectively, while for the "familial" (A beta(A42T)) variant, the MD simulations suggest that a C-terminal beta-strand is stabilised, which could explain the fibrillation. The simulations for the Arctic (A beta(E22G)) variant indicate that the alpha-helix is kept for 2 ns, but reappears 2 ns later, whereafter it disappears after 10 ns. The MD results are in several cases compatible with known experimental data, but the correlation is not perfect, indicating that multimerisation tendency and other factors might also be important for fibril formation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18058241     DOI: 10.1007/s10822-007-9155-6

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  33 in total

Review 1.  The molecular pathology of CJD: old and new variants.

Authors:  G S Jackson; J Collinge
Journal:  Mol Pathol       Date:  2001-12

2.  Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation.

Authors:  D H Chui; H Tanahashi; K Ozawa; S Ikeda; F Checler; O Ueda; H Suzuki; W Araki; H Inoue; K Shirotani; K Takahashi; F Gallyas; T Tabira
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

3.  3D structure of Alzheimer's amyloid-beta(1-42) fibrils.

Authors:  Thorsten Lührs; Christiane Ritter; Marc Adrian; Dominique Riek-Loher; Bernd Bohrmann; Heinz Döbeli; David Schubert; Roland Riek
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-17       Impact factor: 11.205

4.  Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides Abeta40 and Abeta42: stable trimer or tetramer formation by Abeta42.

Authors:  Yun-Ru Chen; Charles G Glabe
Journal:  J Biol Chem       Date:  2006-06-29       Impact factor: 5.157

5.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

6.  Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type.

Authors:  E Levy; M D Carman; I J Fernandez-Madrid; M D Power; I Lieberburg; S G van Duinen; G T Bots; W Luyendijk; B Frangione
Journal:  Science       Date:  1990-06-01       Impact factor: 47.728

7.  Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features.

Authors:  W Kabsch; C Sander
Journal:  Biopolymers       Date:  1983-12       Impact factor: 2.505

8.  Stabilization of discordant helices in amyloid fibril-forming proteins.

Authors:  Anna Päiviö; Erik Nordling; Yvonne Kallberg; Johan Thyberg; Jan Johansson
Journal:  Protein Sci       Date:  2004-05       Impact factor: 6.725

9.  A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene.

Authors:  G Rossi; G Giaccone; R Maletta; M Morbin; R Capobianco; M Mangieri; A R Giovagnoli; A Bizzi; C Tomaino; M Perri; M Di Natale; F Tagliavini; O Bugiani; A C Bruni
Journal:  Neurology       Date:  2004-09-14       Impact factor: 9.910

10.  Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases.

Authors:  Monica Bucciantini; Elisa Giannoni; Fabrizio Chiti; Fabiana Baroni; Lucia Formigli; Jesús Zurdo; Niccolò Taddei; Giampietro Ramponi; Christopher M Dobson; Massimo Stefani
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

View more
  3 in total

1.  Molecular dynamics simulations of pro-apoptotic BH3 peptide helices in aqueous medium: relationship between helix stability and their binding affinities to the anti-apoptotic protein Bcl-X(L).

Authors:  Dilraj Lama; Ramasubbu Sankararamakrishnan
Journal:  J Comput Aided Mol Des       Date:  2011-04-27       Impact factor: 3.686

2.  Unfolding of the amyloid β-peptide central helix: mechanistic insights from molecular dynamics simulations.

Authors:  Mika Ito; Jan Johansson; Roger Strömberg; Lennart Nilsson
Journal:  PLoS One       Date:  2011-03-07       Impact factor: 3.240

3.  Effects of ligands on unfolding of the amyloid β-peptide central helix: mechanistic insights from molecular dynamics simulations.

Authors:  Mika Ito; Jan Johansson; Roger Strömberg; Lennart Nilsson
Journal:  PLoS One       Date:  2012-01-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.